Mesalazine is an aminosalicylate that is used routinely to induce and maintain remission in chronic inflammatory bowel disease – ulcerative colitis and Crohn’s disease.
Asacol and Octasa are also licensed for the maintenance of remission in Crohn’s ileo-colitis. The maximum dose for the 400mg preparations is 2.4g daily. Asacol MR, Ipocol and Octasa MR are all similar in terms of formulation, all enteric coated with Eudragit S, optimal pH for drug release and site of release. Although Octasa MR has not been compared to Asacol 400mg MR in a clinical trial there is in vitro evidence that the products are comparable as Octasa MR has a virtually identical in vitro dissolution to Asacol MR.